Analgesic effect of topical oral capsaicin gel in burning mouth syndrome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. / Jørgensen, Mette Rose; Pedersen, Anne Marie Lynge.

I: Acta Odontologica Scandinavica, Bind 75, Nr. 2, 2017, s. 130-136.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jørgensen, MR & Pedersen, AML 2017, 'Analgesic effect of topical oral capsaicin gel in burning mouth syndrome', Acta Odontologica Scandinavica, bind 75, nr. 2, s. 130-136. https://doi.org/10.1080/00016357.2016.1269191

APA

Jørgensen, M. R., & Pedersen, A. M. L. (2017). Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. Acta Odontologica Scandinavica, 75(2), 130-136. https://doi.org/10.1080/00016357.2016.1269191

Vancouver

Jørgensen MR, Pedersen AML. Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. Acta Odontologica Scandinavica. 2017;75(2):130-136. https://doi.org/10.1080/00016357.2016.1269191

Author

Jørgensen, Mette Rose ; Pedersen, Anne Marie Lynge. / Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. I: Acta Odontologica Scandinavica. 2017 ; Bind 75, Nr. 2. s. 130-136.

Bibtex

@article{919c5e5f931f4344ac973af55a214c4f,
title = "Analgesic effect of topical oral capsaicin gel in burning mouth syndrome",
abstract = "OBJECTIVE: To investigate the effectiveness of repeated topical application of oral capsaicin gel in two different concentrations for relief of burning/stinging sensations in patients with burning mouth syndrome (BMS).MATERIAL AND METHODS: This randomized double-blind cross-over study included 22 female patients with BMS. The patients were randomized for topical application of either 0.01% or 0.025% oral capsaicin gel on the dorsal part of tongue three times daily for 14 days, followed by 14 days wash-out period, and finally treatment with the other concentration of oral gel three times daily for 14 days. A visual analogue scale (VAS) was used to assess the severity of pain five times during the intervention period.RESULTS: 18 patients completed the intervention. Their VAS score at baseline was 5.5 ± 0.6 cm (mean ± SD). Treatment with the two concentrations of capsaicin gels significantly improved the burning/stinging symptoms assessed on VAS compared with baseline (p = 0.002). There was no statistically significant difference between the two concentrations of the gels on relieving symptoms. Four patients dropped out during the intervention period due to gastrointestinal side-effects.CONCLUSIONS: Topical capsaicin might be an alternative for the short-term treatment of BMS. However, further studies are needed to investigate especially the gastro-intestinal side-effects which may limit its long-term use.",
author = "J{\o}rgensen, {Mette Rose} and Pedersen, {Anne Marie Lynge}",
year = "2017",
doi = "10.1080/00016357.2016.1269191",
language = "English",
volume = "75",
pages = "130--136",
journal = "Acta Odontologica Scandinavica",
issn = "0001-6357",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Analgesic effect of topical oral capsaicin gel in burning mouth syndrome

AU - Jørgensen, Mette Rose

AU - Pedersen, Anne Marie Lynge

PY - 2017

Y1 - 2017

N2 - OBJECTIVE: To investigate the effectiveness of repeated topical application of oral capsaicin gel in two different concentrations for relief of burning/stinging sensations in patients with burning mouth syndrome (BMS).MATERIAL AND METHODS: This randomized double-blind cross-over study included 22 female patients with BMS. The patients were randomized for topical application of either 0.01% or 0.025% oral capsaicin gel on the dorsal part of tongue three times daily for 14 days, followed by 14 days wash-out period, and finally treatment with the other concentration of oral gel three times daily for 14 days. A visual analogue scale (VAS) was used to assess the severity of pain five times during the intervention period.RESULTS: 18 patients completed the intervention. Their VAS score at baseline was 5.5 ± 0.6 cm (mean ± SD). Treatment with the two concentrations of capsaicin gels significantly improved the burning/stinging symptoms assessed on VAS compared with baseline (p = 0.002). There was no statistically significant difference between the two concentrations of the gels on relieving symptoms. Four patients dropped out during the intervention period due to gastrointestinal side-effects.CONCLUSIONS: Topical capsaicin might be an alternative for the short-term treatment of BMS. However, further studies are needed to investigate especially the gastro-intestinal side-effects which may limit its long-term use.

AB - OBJECTIVE: To investigate the effectiveness of repeated topical application of oral capsaicin gel in two different concentrations for relief of burning/stinging sensations in patients with burning mouth syndrome (BMS).MATERIAL AND METHODS: This randomized double-blind cross-over study included 22 female patients with BMS. The patients were randomized for topical application of either 0.01% or 0.025% oral capsaicin gel on the dorsal part of tongue three times daily for 14 days, followed by 14 days wash-out period, and finally treatment with the other concentration of oral gel three times daily for 14 days. A visual analogue scale (VAS) was used to assess the severity of pain five times during the intervention period.RESULTS: 18 patients completed the intervention. Their VAS score at baseline was 5.5 ± 0.6 cm (mean ± SD). Treatment with the two concentrations of capsaicin gels significantly improved the burning/stinging symptoms assessed on VAS compared with baseline (p = 0.002). There was no statistically significant difference between the two concentrations of the gels on relieving symptoms. Four patients dropped out during the intervention period due to gastrointestinal side-effects.CONCLUSIONS: Topical capsaicin might be an alternative for the short-term treatment of BMS. However, further studies are needed to investigate especially the gastro-intestinal side-effects which may limit its long-term use.

U2 - 10.1080/00016357.2016.1269191

DO - 10.1080/00016357.2016.1269191

M3 - Journal article

C2 - 28007005

VL - 75

SP - 130

EP - 136

JO - Acta Odontologica Scandinavica

JF - Acta Odontologica Scandinavica

SN - 0001-6357

IS - 2

ER -

ID: 170368300